secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2022-04-27T23:59:59+00:00
Accession:  0001564590-22-016110
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Q1 2022 net loss $16.1M; VK2809 enrollment continues, VK2735 Phase 1 ongoing
--------------------------------------------------------------------------------

- Net loss $16.1M ($0.21/share) vs $14.0M ($0.19/share) in Q1 2021; R&D up to $12.6M.
- Cash and investments $184.9M at March 31, 2022, down from $202.1M at Dec 31, 2021.
- Phase 2b VOYAGE study of VK2809 for NASH expects to complete enrollment in 2H22.
- Phase 1 trial of dual GLP-1/GIP agonist VK2735 ongoing; results expected by year-end.
- VK0214 for X-ALD on clinical hold, expects to submit requested preclinical data to FDA in 2Q22.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000156459022016110/0001564590-22-016110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000156459022016110/vktx-8k_20220427.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-016110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer